virus will be injected into another primate. The primates will nonitored 
for adverse effects. 
Dr. Murray asked if submitters should be required to do experiments in 
addition to those that would be required by the FDA. Dr. Motulsky said he 
thought that Dr. Anderson was paying an exceptional anount of attention to 
hypothetical hazards. 
Dr. Anderson noted that pages 62-69 of the document are written as a clinical 
protocol although it is not being submitted formally as a protocol. 
In response to a question frcm Dr. Gorcvitz regarding an alternative approach 
to enzyme replacement for ADA deficiency cited on page 13 of the submission. 
Dr. Anderson said that it is too early to knew how effective this approach 
might be. This approach involves injection of bovine ADA conjugated to 
polyethylene-glycol. Dr. Kelley noted this treatment would be analogous to 
administering insulin to a diabetic; it would need to be repeated at 
regular intervals for each patient. 
After hearing Dr. Anderson's summary, the subcommittee agreed that the 
document should be considered a preliminary draft of a proposal and 
submitted for review by outside consultants who will be asked to submit 
written comments that will become part of the public record of review. 
Names of potential consultants were suggested to the executive secretary. 
III. General Information Document 
Ms. Witherby suimarized the latest draft of a general information document 
on gene therapy which had been prepared on April 23, 1987. 
Dr. Mac Kay of the NIH suggested that the document needs additional infor- 
mation about gene therapy itself. Several other changes were suggested 
by members of the subcommittee and liaison representatives. Dr. Walters 
said that he would take the comments into consideration and prepare a 
revised draft of the document. 
IV. Adjournment 
The meeting was adjourned at 2:30 p.m. 
[ 204 ] 
Recombinant DNA Research, Volume 1 1 
